ZS Company in 2026: The Firm Zoltners and Sinha Built

Is the ZS company you mean this one?

Three separate companies answer to ZS, and only one of them is a consulting firm. Sorting them takes one line each.

The practical test is the word that travels with the letters. A stock quote, a quarter or an earnings date points at Zscaler. A Virginia address or a staffing service points at the Virginia company. A pharmaceutical client, a sales force or a platform called ZAIDYN points at the firm described here.

One more naming detail is worth settling. The firm was long known as ZS Associates, and a great deal of published material still calls it that. Its own site and its own job postings now say ZS. Both names refer to the same company, and this page uses the short form because the firm does.

That matters for anyone searching. Our ZS case interview guide sits under the longer name for the same reason: the older form is what candidates still type.

What the ZS company name stands for

ZS stands for Zoltners and Sinha. The firm glosses its own initials in a single parenthesis, inside an article it published for its fortieth anniversary.

The anniversary piece describes the founders' research turning into "a small side business", and names that business in a parenthesis of its own: "ZS (Zoltners and Sinha)". The founders' legal names, given in a later press release, are Andris A. Zoltners and Prabhakant Sinha. The firm calls them Andy and Prabha.

The origin story is not the one usually told, and ZS tells the real sequence itself. "Andy and Prabha met in 1973 at the University of Massachusetts, where they collaborated on a multiple-choice knapsack algorithm to plan meals for the U.S. military." Northwestern came afterward: "After earning their doctorates, Andy and Prabha became professors at Northwestern University."

So the firm grew out of a mathematics problem about feeding soldiers, and the two men were at Massachusetts before they were at Northwestern. A profile that opens with two Northwestern professors has compressed away ten years that ZS chose to print.

There is one more detail, and the firm clearly enjoys it. In the pricing case ZS publishes for candidates, the client company is called Zoltners and the drug is called SINHA. The exercise is named after the two founders.

How ZS describes its own business

ZS leads with a purpose sentence rather than a service list, and the sentence is short enough to quote whole.

Its about page reads: "ZS is a management consulting and technology firm that partners with companies to improve life and how we live it. We transform ideas into impact by bringing together data, science, technology and human ingenuity to deliver better outcomes for all."

Two words in that sentence do real work. Technology firm is half the self-description, which is unusual for a consultancy and is backed by a licensed product line described further down this page. And partners with companies places the firm alongside a client team rather than above it.

The client scale it publishes is countable: "1,700+" customers in "170+ countries," read on 8 October 2026. That is a client count rather than an engagement count, and ZS gives no date for the measurement.

What the page does not contain is any amount of money. There is no revenue figure, no fee range and no deal size. For a firm that counts its customers to the hundred, the absence is a choice rather than an oversight.

Five industries in the menu, and the one that is missing

ZS lists five industries in its live navigation, and life sciences is not one of them. Pharmaceutical work sits inside Healthcare, which is the opposite of how the firm's own vocabulary reads.

Counted off the navigation fragment on 8 October 2026, the five are Consumer Goods & Retail, Financial Services, Healthcare, Technology & Telecommunications, and Travel & Hospitality.

Then look at what the healthcare page actually promises. The healthcare page describes work "from drug development to commercialization, payers and providers to patient experience," and claims "40+ years spent on technology and healthcare." Those are drug industry words. ZAIDYN, the firm's platform, is described on its own page as "a life sciences intelligence platform."

So the structure says five industries and the language says one specialty with four neighbors. Both readings are true, and which one matters depends on the role you are applying to. A consumer goods opening at ZS is real, and the firm's published practice case about sunscreen proves it treats that work seriously.

For the sector context, our pharmaceutical consulting page sets out how seven firms including this one label the same work, and the labels disagree across all of them.

Nine capabilities, counted off the navigation

ZS organizes what it sells into nine capabilities, and two of the nine are named in the vocabulary of the drug industry rather than of general management.

The navigation fragment read on 8 October 2026 lists them as AI & Analytics, Customer Experience, Data, Digital & Technology, Marketing, Research & Development, Sales, Strategy & Transformation, Supply Chain & Manufacturing, and Value & Access. The firm frames the group this way: "Find out how we use consulting and technology expertise to help companies build the capabilities they need to grow."

Value & Access is the giveaway. In life sciences it means market access, pricing and reimbursement, which is the work of getting a drug paid for. Research & Development is the second. Neither label would appear in the navigation of a generalist strategy firm.

Two more capabilities tell you what a junior analyst will spend time on. Sales and Marketing are listed as capabilities in their own right, which fits the firm's origin in sales force sizing. The founders' first commercial idea was a method for deciding how many representatives to deploy, and that line of work is still a menu item four decades later.

Set against five industries, nine capabilities give forty-five possible pairings. ZS does not publish how the work splits across them, so the grid is a map of what is offered rather than of where the revenue sits.

ZAIDYN, and the software ZS has shipped since 1986

ZS licenses software, and it has done so for about forty years. The platform called ZAIDYN is the consolidation of three older product lines, and the firm said so on the day it launched it.

The launch release, dated Evanston, 14 September 2021, carries the sentence that settles it: "Today, we are announcing ZAIDYN, expanding on more than 35 years of software expertise from our JAVELIN, VERSO and REVO product lines." Thirty-five years before 2021 is 1986, which is three years after the firm was founded. The software business is nearly as old as the advisory business.

The same release gives the adoption figures at launch: "More than 130 companies already use ZS's products to drive business decisions, and over 100,000 pharmaceutical field reps worldwide use ZS insights to engage their customers."

The product page read on 8 October 2026 gives the current set, and the numbers have moved.

The last two rows are vendor claims about outcomes, with no method and no sample attached, so read them as marketing rather than as measurement. The first three are counts, which is a different kind of statement.

Three more products sit in the navigation: Personalize.AI, Trials.ai and ZS Atlas Intelligence. ZS says Personalize.AI earned the firm its first patent, which it dates to 2024.

Three office counts and two country counts, all live

ZS publishes 15,000-plus people consistently and then disagrees with itself about where they sit. Three of its own pages, read on the same day, give three different pictures.

Two pages say forty-plus offices and one says thirty-five-plus. On client countries the gap is wider: 170-plus against over 70, a factor of about 2.4 between two pages of the same site. Neither figure carries a measurement date.

The honest reading is that ZS has somewhere above 15,000 people in roughly 40 offices as of October 2026, with the offices page lagging. Spread 15,000 people across 40 offices and the average is 375 each, which is our arithmetic and not the firm's, and which an unevenly sized footprint makes a weak average.

There is a second trap in the archive. ZS press releases from 2021 are still live and still say "more than 13,000 employees in over 35 offices worldwide." The fortieth anniversary article says 13,000-plus. Content from 2024 says about 14,000 in 39 offices. Quoting any of those as current is quoting a date rather than a fact, and the date is in the URL.

The revenue figure ZS does not print

ZS publishes no revenue. We looked on eight of its own pages and ran two scoped searches of its domain, and the firm states one growth rate for one year and no amount ever.

The growth rate sits inside a 2021 press release and is attributed to the outgoing chief executive: Chris Wright "oversaw the company's 30% growth in 2020." That is one year, one percentage, with no base and no currency.

The figure near three billion dollars that appears in search results for this firm comes from third-party estimators that model private company revenue. It is not a ZS statement, and it does not appear on any ZS page we read. Nothing here attributes it to the firm.

One document could still hold a number, and the honest status is that we could not read it rather than that it does not exist. The firm's 2024 environmental and social report downloads cleanly as a five-megabyte PDF, and its text layer resisted three attempts: a direct request with a browser user agent, programmatic stream extraction, and a reading service that reported the file as encoded binary. If ZS prints a financial figure anywhere, that report is where it would be.

ZS is privately held, so nobody files its accounts. That explains the absence without excusing an estimate, and it is the same position several firms in our types of consulting firms comparison hold.

A chief executive elected by partners, for a capped term

ZS replaces its leader by election, with a term limit, and it published both facts in the same press release. Very few firms of this size describe their succession mechanism at all.

The succession release, dated 28 July 2021, states that Pratap Khedkar "has been elected to CEO by the firm's leaders." Then it explains the design: "Khedkar is the third CEO in ZS's nearly 40-year history. He was elected by his peers, a structure ZS's founders Andris A. Zoltners and Prabhakant Sinha established to ensure cultural continuity."

The term limit is stated as plainly: Khedkar "succeeds Chris Wright, who served the firm's maximum term." Three chief executives in thirty-eight years follows from that arithmetic rather than from luck.

Two other names are published in the same place. Jaideep Bajaj is chairman of the board and "held the position of CEO from 2003 to 2012." Sandra Forero was appointed to a newly created chief operating officer role. The current CEO's name also appears under a signed statement on the firm's people page, which is how we verified it is still him.

Khedkar's background is published too, and it fits the technology half of the self-description: a doctorate in artificial intelligence from Berkeley and an engineering degree in computer science from IIT Delhi. The firm picked a technologist to run a consultancy.

What ZS built and bought in 2024

ZS prints a dated list of what it did in 2024, which is more operational detail than most private firms release about a single year. Five items are worth carrying.

1. An operations center in Hyderabad, India, which ZS describes as its first.
2. An acquisition, Digital Additive, "a firm specializing in Salesforce-powered solutions." That is the firm buying capability in a commercial platform rather than in a sector.
3. More than 2,850 promotions, a headcount-relative figure the firm chose to publish. Against 15,000-plus people that is roughly one in five, which is our arithmetic on their two numbers.
4. Its first patent, for Personalize.AI, described as "a software-as-a-service (SaaS) solution that delivers tailored customer engagement through AI-driven insights."
5. Myelo, a generative chatbot built with the International Myeloma Foundation, which is a named non-commercial partner rather than an unattributed good deed.

Read items two and four together. A Salesforce acquisition and a software patent in the same year describe a firm investing in product and in platform integration rather than in sector coverage. That is consistent with a company that has sold licensed software since 1986.

The 2026 recognitions ZS lists on its homepage are of a different kind, including a Forbes listing and a sustainability rating. Those are third-party judgments, and this page does not rank firms, so they are noted as claims the firm makes about itself rather than as standings.

Six entry titles, and the degree each one asks for

ZS opens more than one junior door, and the titles differ in what they demand. Read off its live job board on 8 October 2026, six exist.

The first column is the useful part. A candidate from a humanities background has one honest route, the Strategy Insights & Planning track, because it is the only one whose posting says any discipline. The Decision Analytics and Business Technology routes name fields, and a posting that names fields is a filter.

One caveat on method belongs here. A direct request for an individual posting returned a 404 inside a JavaScript shell on 8 October 2026, so the two newest titles were confirmed through the search index of those same URLs rather than from a posting we parsed ourselves. The four older titles were read from the postings' own structured data on 29 September 2026.

For what happens after you apply, ZS names four interview types and a range of two to four rounds, and it publishes three complete practice cases with answers. All of that sits in our ZS case interview guide, which quotes the firm's own wording.

What ZS does not publish about itself

Every page above answered a direct request with a browser user agent on 8 October 2026. The archive and the reading proxy were needed only for the report noted below. Here is what none of these pages answers.

• Revenue, in any year, in any currency. Eight pages and two scoped searches of the domain produced one growth rate for 2020 and no amount. This is a non-publication rather than a blocked page.
• Revenue or client mix by industry. The about page counts clients and countries and splits neither.
• The number of countries containing a ZS office. The firm publishes client countries and office cities, and never a count of countries with an office in them.
• A per-city office list from the site itself. The map on the offices page is served inside a third-party interactive frame, so the city names are absent from the HTML and we did not enumerate them.
• The 2024 environmental and social report's figures. The file downloads and its text layer defeated three reading methods. The right sentence is that we could not read it.
• A headquarters postal address. The about, offices and contact paths route to a form and to a press agency.
• Pay. None of the postings we read carried a band, and no ZS page aggregates compensation.
• An acceptance rate, for any program or office. No figure exists on any ZS page, and any percentage you find has been reconstructed from outside the firm.

One absence worth naming separately is a first-hand account. We looked for a candidate or employee narrative that ZS did not itself publish, and found none we could attribute. Everything above is the firm describing itself.

How we score a brainstorm, and why it fits this firm

A firm whose capabilities include Value & Access and whose origin is sales force sizing asks a lot of questions with no single right answer. The habit that pays on those is generating options in named groups rather than one at a time.

These are the dimensions our own grader measures on a brainstorm, with the weight each carries out of a hundred. The weights are ours, and no firm publishes one.